RAD-140 vs LGD-4033
There is no winner on this page. What is set side by side is the published record behind each one, which is the part the two are rarely compared on.
Both in SARMs
The two most bought compounds on this shelf, and their gaps run in opposite directions. LGD-4033's convention sits five to fifteen times above the top dose of either trial, and the one published case report giving a daily amount describes severe liver injury at 10 mg. RAD-140's sits below what was studied, which is not reassurance: those doses were given to women with metastatic breast cancer under supervision, with blood tests, and the trial still raised one liver enzyme in 59.1 percent of them. Below a studied dose is a statement about arithmetic, not about safety.
| Field | RAD-140 | LGD-4033 |
|---|---|---|
| What a trial gave | 50 to 150 mg a day, with 100 mg set as the maximum toleratedA completed phase 1 in women with metastatic breast cancer | 1.0 mg a day for 21 days, and 2.0 mg a day for 12 weeksA phase 1 in 76 healthy men and a phase 2 in 108 hip fracture patients |
| What circulates | 20 to 30 mg a day for men, on an eight week cycle | 10 mg a day for men over 8 to 10 weeks, up to 15 for experienced users |
| The gap | Below the studied dose | Above the studied dose |
| How long it lasts | I could not find a published human half life. The completed phase 1 established a maximum tolerated dose rather than a pharmacokinetic profile in the material the class page research reached. | I could not find a published human half life in the material behind the class page. The dosing in both trials was once daily. |
| Route studied | By mouth, daily, at 50, 100 or 150 mg, in women with metastatic breast cancer. A second study is recruiting under the code EP0062, and that registry record never names RAD-140, so the identity link runs through a chemical database synonym list. | By mouth, once a day. The phase 1 randomised 76 healthy men aged 21 to 50 to a dummy or to 0.1, 0.3 or 1.0 mg for 21 days. The phase 2 randomised 108 people aged 65 and over to a dummy or to 0.5, 1.0 or 2.0 mg for 12 weeks. |
| Route used | By mouth, at 20 to 30 mg a day on an eight week cycle, reported as convention and not as a recommendation. | By mouth, at 10 mg a day for men over an 8 to 10 week cycle and up to 15 mg for experienced users, reported as convention and not as a recommendation. |
| Vial sizes | No vial size named in the entry | No vial size named in the entry |
The distance, stated
Below the studied dose
RAD-140
This one runs the opposite way to the rest of the shelf: what circulates sits below what was studied rather than above it. The completed trial gave 50 mg a day to six patients, 100 mg to thirteen and 150 mg to three, and set the maximum tolerated dose at 100 mg. The page publishing the 20 to 30 mg figure cites no human study for it. Sitting under a studied dose is not a safety finding, because that trial was in women with metastatic breast cancer taking it under supervision, and it raised one liver enzyme in 59.1 percent of them.
Above the studied dose
LGD-4033
Five to fifteen times the top dose of either trial. The 21 day phase 1 randomised 76 healthy men to a dummy or to 0.1, 0.3 or 1.0 mg, and the 12 week phase 2 in people recovering from a hip fracture topped out at 2.0 mg. The guide page carrying the 10 to 15 mg figures also tells readers that clinical trials support up to 222 mg a day for 14 days; its citation list has two entries, and the only trial among them is the 21 day study whose highest dose was 1.0 mg. The one published case report that gives a daily amount describes severe liver injury at 10 mg.
What people get wrong
RAD-140
The trap here is the direction of the dose gap. Almost everything else in this reference is sold above what was studied; this is sold below it. That is not reassurance. The studied doses were given to people with metastatic cancer under supervision, with blood tests, and the trial still raised liver enzymes in most of them.
LGD-4033
The trial doses and the market doses are not the same order of magnitude, and one guide page bridges the gap with a sentence that does not survive checking: it tells readers clinical trials support up to 222 mg a day for 14 days. Its citation list has two entries, and the only trial among them is the 21 day study whose highest dose was 1.0 mg.
Every figure above is carried across from each compound’s entry, which is where the citations live.
All 65 compounds on one page at what circulates vs what was studied, or pick another two to compare.